ADC Therapeutics SA (ADCT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.61

From 52W high−65.57%

Volume1.63M

Market cap$214.48M

P/E (TTM)—

P/S (TTM)2.7x

Div yield—

Key dataNov 4, 2026

Open

$1.61

From 52W high

−65.57%

Volume

1.63M

Market cap

$214.48M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.7x

P/E (TTM)

—

RSI (14)

57.9

MomentumView details →

1D Return

+8.39%

YTD Return

−53.97%

SummaryUpdated Jun 1, 2026

ADC Therapeutics SA (NASDAQ:ADCT) is a commercial-stage biotechnology company founded in 2011 and headquartered in Epalinges, Switzerland. The company went public in May 2020 and specializes in developing antibody drug conjugates (ADCs) for treating blood cancers and solid tumors. ADC Therapeutics has successfully commercialized its flagship product <b>ZYNLONTA</b> and is advancing multiple clinical-stage programs targeting various cancer indications. The company operates with a focused strategy on hematological malignancies while maintaining a selective solid tumor pipeline.

Ask drillr about ADC Therapeutics SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.7x

EV/Sales

5.2x

P/S (TTM)

2.7x

P/B (TTM)

−0.9x

ProfitabilityView details →

Gross Margin

88.75%

Net Margin

−123.03%

EBITDA Margin

−111.21%

ROE (TTM)

42.47%

ROA (TTM)

−34.69%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

+1.97%

EPS YoY

+57.80%

FCF YoY

+20.00%

Revenue CAGR 3Y

−27.09%

EPS CAGR 3Y

+30.86%

EBITDA YoY

+24.12%

MomentumView details →

1D Return

+8.39%

YTD Return

−53.97%

1Y Return

−59.68%

RSI (14)

57.9

vs 50D SMA

+22.17%

vs 200D SMA

−33.95%

Capital & dividendView details →

Debt/Equity

−1.83x

Current Ratio

3.03x

Quick Ratio

2.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

49.07%

Beats (12Q)

8/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

21.19%

Rev Surprise

1.91%

Financials snapshotView financials →

Revenue (TTM)

78.77M

Net Income (TTM)

−96.91M

Op. CF (TTM)

−102.27M

Next earningsNov 9, 2026 →

Latest newsMore news →

ADC Therapeutics submitted abstracts for LOTIS-5, LOTIS-7, and MZL IIT data for presentation at the 68th ASH Annual Meeting and Exposition.83d ago

ADC Therapeutics held a pre-sBLA meeting with the U.S. FDA to discuss LOTIS-5 data and is assessing the regulatory path for full approval of ZYNLONTA.83d ago

Similar companies

Palisade Bio, Inc.PALI InflaRx N.V.IFRX Keros Therapeutics, Inc.KROS ProKidney Corp.PROK Evommune, Inc.EVMN Immunotech Biopharm Ltd06978.HK Find similar companies →

Latest newsMore news →

ADC Therapeutics submitted abstracts for LOTIS-5, LOTIS-7, and MZL IIT data for presentation at the 68th ASH Annual Meeting and Exposition.83d ago ADC Therapeutics held a pre-sBLA meeting with the U.S. FDA to discuss LOTIS-5 data and is assessing the regulatory path for full approval of ZYNLONTA.83d ago ADC Therapeutics reported second quarter 2026 financial results, with net product revenue of $18.6 million and cash and cash equivalents of $219.1 million as of June 30, 2026.83d ago